Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Merck & Co., Inc. < Previous 1 2 ... 6 7 8 9 10 11 12 13 Next > The Medicines Patent Pool (MPP) and Merck Enter Into License Agreement for Molnupiravir, an Investigational Oral Antiviral COVID-19 Medicine, to Increase Broad Access in Low- and Middle-Income Countries October 27, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Announces Positive Top-Line Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily Oral Fixed Dose Combination of Doravirine/Islatravir for the Treatment of People with HIV-1 Infection October 25, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck and Ridgeback Announce Initiation of a Rolling Review by the European Medicines Agency for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of COVID-19 in Adults October 25, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK European Commission Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy as Treatment for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer (TNBC) October 22, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK CDC ACIP Unanimously Votes to Provisionally Recommend Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Series with PNEUMOVAX ® 23 (Pneumococcal Vaccine Polyvalent) as an Option for Pneumococcal Vaccination in Appropriate Adults October 20, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Issues Voluntary Nationwide Recall of CUBICIN® (daptomycin for injection) 500 mg, Lot 934778, Due to Presence of Particulate Matter Identified as Glass Particles October 19, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck and Eisai Receive Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Two Different Types of Cancer October 15, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Individuals 18 Years of Age and Older October 15, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy, With or Without Bevacizumab, as Treatment for Patients With Persistent, Recurrent or Metastatic Cervical Cancer Whose Tumors Express PD-L1 (CPS ≥1) October 13, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Begins Tender Offer to Acquire Acceleron Pharma Inc. October 12, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck and Ridgeback Announce Submission of Emergency Use Authorization Application to the U.S. FDA for Molnupiravir, an Investigational Oral Antiviral Medicine, for the Treatment of Mild-to-Moderate COVID-19 in At Risk Adults October 11, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck and Emmy-Nominated Actress Yvonne Orji Unveil Uncovering TNBC, Highlighting the Challenges Faced by Black Women Diagnosed with Triple-Negative Breast Cancer October 05, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck and Ridgeback’s Investigational Oral Antiviral Molnupiravir Reduced the Risk of Hospitalization or Death by Approximately 50 Percent Compared to Placebo for Patients with Mild or Moderate COVID-19 in Positive Interim Analysis of Phase 3 Study October 01, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck to Acquire Acceleron Pharma Inc. September 30, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Announces Appointment of Thomas H. Glocer as Independent Lead Director September 29, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck to Hold Third-Quarter 2021 Sales and Earnings Conference Call on October 28 September 28, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Announces KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Overall Survival (OS) in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib September 27, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK LYNPARZA® (olaparib) in Combination With Abiraterone Significantly Delayed Disease Progression in Patients Regardless of Biomarker Status in PROpel Phase 3 Trial in First-Line Metastatic Castration-Resistant Prostate Cancer (mCRPC) September 24, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Reduced Risk of Death by 27% Versus Chemotherapy as First-Line Treatment for Patients With Metastatic Triple-Negative Breast Cancer Whose Tumors Expressed PD-L1 (CPS ≥10) September 19, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck’s KEYTRUDA® (pembrolizumab) Demonstrated Superior Recurrence-Free Survival (RFS) in Patients With Resected High-Risk Stage II Melanoma Compared to Placebo in the Adjuvant Setting September 18, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Death by One-Third Versus Chemotherapy With or Without Bevacizumab as First-Line Treatment for Persistent, Recurrent or Metastatic Cervical Cancer September 18, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) in Combination With Chemotherapy for Certain Patients With Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer Whose Tumors Express PD-L1 (CPS ≥10) September 17, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck To Present New Data From Its Broad Oncology Portfolio and Pipeline at ESMO 2021, Including in Earlier Stages of Cancer September 08, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck to Present at the Morgan Stanley 19th Annual Healthcare Conference September 07, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck’s KEYTRUDA® (pembrolizumab) Approved in China in Combination With Chemotherapy for First-Line Treatment of Patients With Locally Advanced Unresectable or Metastatic Esophageal or Gastroesophageal Junction (GEJ) Carcinoma September 07, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck and Ridgeback Biotherapeutics Announce Initiation of Pivotal Phase 3 MOVe-AHEAD Study Evaluating Molnupiravir for Post-Exposure Prophylaxis of COVID-19 Infection September 01, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK FDA Approves Updated Indication for Merck’s KEYTRUDA® (pembrolizumab) for Treatment of Certain Patients With Urothelial Carcinoma (Bladder Cancer) August 31, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck’s KEYTRUDA® (pembrolizumab) Receives Two New Approvals in Japan August 26, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK Merck Announces VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Met Key Immunogenicity and Safety Endpoints in Phase 3 Pivotal Trial Evaluating Use in Infants, PNEU-PED (V114-029) August 25, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK Leslie A. Brun Resigns from Merck Board of Directors August 20, 2021 From Merck & Co., Inc. Via Business Wire Tickers MRK < Previous 1 2 ... 6 7 8 9 10 11 12 13 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.